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3Merck’s Adenovirus-Based Vaccines
• Replication-incompetent adenovirus 
– E1 deficient
– Propagated in E1-complementing cell line 
(PER.C6™)
• For HIV Vaccine, incorporates 
transgenes for HIV-1 gag, pol, and nef
– Could incorporate any gene of interest
• Monovalent or multivalent
– Single construct or multiple constructs
– Mono-gene or multi-gene
Fuller et al., 
Cell 1991
Adenovirus 
reconstruction from 
Cryo-EM
4How Was it Designed to Work?
Presented by MHC to T-Cells Immune Response
•No functionality
•Polypeptide sequence only is 
critical
5Hope and Disappointment in HIV 
Vaccine Development at Merck
• Phase I studies showed strong immune response in 
recipients
– Animal studies had shown reduction in viral load
• Phase II studies, initiated in 2004, were designed to test 
if the immune response elicited was sufficient for efficacy
• Disappointingly, the results from Phase II (Sept. 2007) 
suggested that the measured ELISPOT was not 
indicative of efficacy
6Why Discuss it Further?
• Hopefully others can learn from this, and speed 
development of other HIV vaccines
– "If I have seen further, it is by standing on the shoulders of giants.”  
--Sir Isaac Newton, 1675
– Other Adenovirus-based vaccines are being developed
• Merck was preparing for Phase III and potential 
launch
– This is a good case study for how to move toward 
“well-characterized” live virus vaccines
7Ensuring Quality Through 
“Cradle-to-Grave” Analytics
Viral 
Seeds
In-Process
Monitoring
Drug 
Substance
Drug
Product
Stability
“Well-Characterized” should 
reflect the entire process, not just 
the end product
Cell Bank 
(PER.C6)
*Raw material testing is also important at each stage
8What Should This Talk Convey?
1. The extensive analytical complexity of 
this program as a whole
2. How we have been able to get our arms 
around this complexity
Attention to detailed science makes a 
difference in true understanding and control
9Unique Challenges in Adenovirus-
Based Analytics:  Sub-Populations
Total Virus Particles
Safety?
Full Particles 
Safety?  Efficacy?
Infectious Particles 
Efficacy?  Productivity in manufacturing.
Antigen Expressing Particles 
Efficacy?  Residuals in manufacturing.
Empty ParticlesFull Particles
Total Virus Particles
Infectious Particles
Antigen Expressing Particles
Transgene-encoded 
Antigen
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Critical Analytical Characterization
Identity
StrengthPurity
Potency
QUALITY
Need to assess these attributes for all sub-populations of viral particles
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Breadth and Depth
• Each of the subsequent slides could 
have 20 slides describing the story 
behind it
• The goal of this talk is not to “wow” 
you with detailed data, but to 
illustrate the variation and 
complexity (and sheer numbers) of 
problems we faced and how we 
overcame them
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General Manufacturing Scheme
GROWTH IN PER.C6 
CELLS
↓
(AUTO)LYSIS
↓
CLARIFY
↓
NUCLEASE
↓
UF
↓
AEX
↓
2nd CHROMATOGRAPHY
↓
UF
Sources: Huyghe, 1995; Misc Patent 
Applications (Introgen, Aventis, Canji, Schering)
The end product is a 
purified preparation of 
Adenovirus particles 
Identity and Purity
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•Unexpected bands observed in all digests suggesting possible deletions
•Led to cloning of fragments, sequence identification, ultimately 
potentially to re-design of original plasmid construct
Challenges With Identity/Purity
A seemingly simple 
observation kicked 
off ~12 months of 
detailed 
investigation, 
ultimately leading 
to a critical 
conclusion.
C. Wang et al
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Purity:  Unique Challenges with 
PER.C6 Cells 
Neuronal cell type from human fetus previously 
unlicensed for use in vaccines 
Prior cell expansion with bovine serum 
Transformed and non-adherent phenotype 
Recombinant E1-encoding expression system
Duncan et al
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Purity:  Extensive Testing to Detect 
Potentially Contaminating Viruses
• Tests in cell lines    
• Test in eggs and 
animals
• Product-enhanced 
reverse transcriptase 
• Electron microscopy
• PCR
Duncan et al
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Purity:  Protein Clearance by SDS-PAGE
Process Intermediates Purified Virus Bulk
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Konz, Soohoo, et al
Tracking clearance through the process gave good 
confidence in the end product purity.
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Purity:  Host Impurity Clearance
•Approximately 7 log clearance in host cell DNA after purification
•Final product is largely free of host contaminants
Konz, Goerke, DiStefano, Pitts, and Sagar
DNAProtein
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Purity:  Quantification of Empty Capsids
Full Empty
Sweeney et al (in prep)
Takahashi E, Cohen SL, Tsai PK, Sweeney JA. Anal Biochem. 15;349(2):208-17 (Feb 2006). 
RP-HPLC
CsCl Gradient Preparation
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•Three methods developed for this 
critical parameter.  
•Orthogonal assays led to increased 
understanding of the process and the 
assays themselves.
Strength and Potency
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Assays for Strength (i.e., Dose)
• Three methods developed:
– Lowry
– UV-SDS1
– Genome Quantitation2
• Key assay attributes
– Accurate, precise, specific, and 
reproducible
– Flexible for multiple constructs
– High throughput, short turn-
around time
Lysis 
SDS & Heat
Real-time QPCR
log (dilution fold)
C
t
standard
sample
+ PCR master mix
Dilute 
Samples
Genome Quantitation (GQA)
1Sweeney, J. and J. P. Hennessey.  Virology. 10;295(2):284-8 (April 2002). 
2Wang L., Wang C. J., Tan C. Y., Hsu D., and Hennessey J. P. Human Gene Therapy. 17: 728-740 (July 2006).
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Strength:  Aggregation Issues
Relatively straight-forward 
measures of aggregation 
(DLS) proved useful for 
this vaccine
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Sweeney et al
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Potency Assay Development
Wang F., Puddy AC,  Mathis BC, et al. Vaccine.  23, 4500-4508 (2005)
Gained precision and specificity in an infectivity assay, but 
vaccine does not replicate in the vaccinee (Biological 
Relevance?)
ELISAQ-PCR
serial dilutions
14 days
add MTS
Plant 
cells
calculation
“Progressive” TCID50
Cell Lysis
Q-PCR
“Parallel-Line”
Analysis 
Infectious Titer
C
t
Lyse 
cells
24 hr
Quantitative PCR-
Based Potency Assay 
(QPA)
serial dilutions
48 hrs
Plant 
cells
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Potency:  In Vitro Antigen Expression (IVAE)
Read Plate
OD 450nm
Solid phase
Store at -70oC
ELISA
Capture mAb
Antigen
Detection  
HRP-mAb
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Cell lysis
Advantages:
• Likely the most relevant measure of vaccine activity; Specific; Precise
Disadvantages:
• Choosing appropriate antibodies was complex and time-consuming
• Consistency and availability of reagents moving forward is challenging
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Concordance of Infectivity and 
Antigen Expression Assays
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¾ Infectivity and antigen expression assay results were similar
¾ Variability was slightly lower in the IVAE 
¾ Both assays appear appropriate as the key potency assay
QPA IVAE
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Analytical and Clinical Data Relationship
•In both the clinical and IVAE data, trivalent vaccine generated slightly 
stronger responses (not statistically significant clinically)
•Only true for “high Ad5” clinical population
•Suggested IVAE might be the more clinically relevant assay
•IVAE has operational disadvantages
M. Robertson, R. Isaacs, R. Leavitt, J. Rolling, R. Reinmiller
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Investment in Assay Development
Total Virus Particles 
Lowry Protein Assay
Dynamic Light Scattering
Full Particles
Genome Quantitation Assay (GQA)
Reverse-Phase HPLC Assay
CsCl Gradient Analysis (% full)
UV Absorbance Assay (UV-SDS)
Disc Centrifugation
Infectious Particles
TCID50
Q-PCR Based Potency Assay (QPA)
Antigen Expressing Particles 
Silver stain/Western blot
In vitro Antigen Expression Assay (IVAE)
Empty ParticlesFull Particles
Total Virus Particles
Infectious Particles
Antigen Expressing Particles
Transgene-encoded 
Antigen
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•Genetic stability
•Manufacture in a 
permissive cell-line
Ensuring Quality Through 
“Cradle-to-Grave” Analytics
Cell Bank 
(PER.C6)
Viral Seeds
(MVS, WS)
In-Process
Monitoring
Drug 
Substance
Drug
Product
Stability•Never-before used in 
human trials
•A lot of safety testing
•DNA digestion
•Protein clearance
•Aggregation
•Defining the 
“active” units of 
safety and efficacy
•Measuring purity
•Biophysical charac.
•2-8 ºC stable
•Narrow window 
for release
There are analytical challenges at each stage
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Are We There Yet?
• Significant understanding of the 
cellular and molecular biology, 
biophysics, and physical chemistry 
of the vaccine has been attained
• Most assays are suitable for 
“platform” testing
• The missing link is clinical efficacy
Defining “well-characterized” depends on the application
30
Acknowledgments
Chris Wang
Liman Wang
Jenny Xu
Diana Pacchione
Jennifer Naspinski
Danielle McElhaugh
Jayanthi Wolf
Liman Wang
Marie-Noëlle Takahashi 
Shawn Zhang
Margie Geary
Judy Rolling
Chris Hamm
Amanda Sheard
Joyce Sweeney
Bettiann Waldner
John Konz
Robin Isaacs
John Lewis
Pei-Kuo Tsai
Mike Robertson
David Hsu
Randy Leavitt
Bob Sitrin
John Hennessey
Paul Duncan
Scott Barmat
GQA QPA IVAE
Biophysical
Many, many others within and outside of Merck
Robyn Reinmiller
31
“We try never to forget that medicine 
is for the people--it is not for the 
profits.  The profits follow, and if we 
have remembered that, they have 
never failed to appear.”
--George W. Merck, December, 1950
